Transcutaneous Electrical Nerve Stimulation Improves Vascular Conductance After Coronary Artery Bypass Graft Surgery (TEBCABG)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The investigators will test the hypothesis that transcutaneous electrical nerve stimulation (TENS) may attenuate peripheral vasoconstriction and to improve blood flow redistribution during handgrip exercise in acute myocardial infarction (AMI) patients after Coronary Arterial Bypass Graft Surgery (CABG).
| Condition | Intervention |
|---|---|
|
Acute Myocardial Infarction |
Device: Transcutaneous electrical nerve stimulation |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | Transcutaneous Electrical Nerve Stimulation Improves Vascular Conductance After Coronary Artery Bypass Graft Surgery |
- Blood flow redistribution - baseline and 5 days later [ Time Frame: 1 day ] [ Designated as safety issue: Yes ]The ultrasound Doppler system will be equipped with two linear array transducers operating at an imaging frequency of 7- 8 megahertz (MHz). The common femoral artery of the left leg will be insonated distal to the inguinal ligament, 2-3 cm proximal to the bifurcation. Using femoral artery diameter and mean blood velocity (MBF), femoral blood flow (FBF) was calculated as MBF π x (vessel diameter/2)2 x 60. Femoral vascular resistance (FVR) and femoral vascular conductance (FVC) were calculated as (MBP/FBF) and (FBF/MBP * 100 mm Hg), the conductance multiplied by 100 mmHg so that the conductance units will be similar to the units of femoral blood flow (10, 45). The magnitude of reduction FVC (expressed in %) was calculated as vascular conductance during exercise (% change) - conductance at rest (% change) expressed by % of baseline.
- Inspiratory and Expiratory Muscle Function [ Time Frame: 5 day ] [ Designated as safety issue: Yes ]Inspiratory and expiratory muscle strength testing were performed using a pressure transducer (MVD-500 V.1.1 Micro Hard System, Global Med, Porto Alegre, Brazil). Maximal inspiratory (PImax), and maximal static expiratory pressure (PEmax) were measured as previously described.
- Pain Intensity [ Time Frame: 5 day ] [ Designated as safety issue: Yes ]A visual analog scale (VAS) for assessing current pain intensity will be used to evaluate pain from 0 to 10, where 0 means no pain and 10 indicates severe pain, being applied on the first and on the 5th day after CABG .
- Opioid Analgesic Amount [ Time Frame: 5 day ] [ Designated as safety issue: Yes ]During the first 24 h (immediately, 6, 12 and 24 h) after CABG, the amount of additional analgesic dose (pethidine hydrochloride (HCl) 20 mg, maximum 1 mg/kg/day) was measured for patients in both groups.
- β-Endorphin Analysis [ Time Frame: 5 day ] [ Designated as safety issue: Yes ]Ten milliliters of venous blood will be taken by the phlebotomist. 3 ml of which will be stored in ethylenediaminetetraacetic acid (EDTA) for analysis of a differential white cell count. Seven ml of blood will be divided between an EDTA tube and a lithium heparin (LH) gel tube. These blood samples will be centrifuged and frozen until assayed. β-endorphin was measured by sandwich enzyme immunoassay (ELISA) kit (Phoenix Pharmaceuticals, Inc., USA).
| Estimated Enrollment: | 40 |
| Study Start Date: | March 2013 |
| Estimated Study Completion Date: | July 2013 |
| Estimated Primary Completion Date: | May 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: TENS CABG
Eligible patients will be randomized to a transcutaneous electrical nerve stimulation program (TENS; n = 20) or to placebo-TENS (P-TENS; n = 18). All patients were followed by their own physicians, received routine nursing assistance, and were visited daily by one of the investigators, but P-TENS group will be not exposed to any specific electrical stimulation or motor physical intervention.
|
Device: Transcutaneous electrical nerve stimulation
Patients will be treated with conventional TENS (ENDOMED 684 Device, ENRAF-Nonius B.V., Rotterdam, Netherlands) for 5 days (4 times/day; 30 min/session) applied on cervical region (C7-T4). TENS intervention was applied as described elsewhere.
Other Names:
|
|
Placebo Comparator: P-TENS CABG
Patients will be treated with placebo-TENS (P-TENS) condition for 5 days (4 times/day; 30 min/session) applied on cervical region (C7-T4). P-TENS device underwent modifications in its internal programming: the control capacitor of the time constant was changed and the active time between pulses was modified from 330 milliseconds to 33 seconds, in order to prevent an analgesic effect (33).
|
Device: Transcutaneous electrical nerve stimulation
Patients will be treated with conventional TENS (ENDOMED 684 Device, ENRAF-Nonius B.V., Rotterdam, Netherlands) for 5 days (4 times/day; 30 min/session) applied on cervical region (C7-T4). TENS intervention was applied as described elsewhere.
Other Names:
|
Detailed Description:
Thirty-eight patients will be randomized to a (4 times/day; 30 min/session) for 5-day program of TENS (n = 20) or to placebo-TENS (P-TENS, n = 18) applied on cervical region (C7-T4). Acute sympathetic stimulation by cold pressor test (CPT), Maximal voluntary contraction (MVC), Femoral blood flow (FBF) and femoral vascular conductance (FVC) will be measured as primary outcome pre and post-CABG, even as the 6-minute walk test (6-MWT), Inspiratory and expiratory muscle strength (PImax and PEmax) and β-endorphin as a secondary clinical parameters. In addition, amount of opioid analgesic and pain intensity also will be measured throughout at first 24 hours after CABG (immediately, 6, 12 and 24 hours).
Eligibility| Ages Eligible for Study: | 48 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- a previous history of more than 1 vessel coronary artery disease,
- lifelong abstinence from tobacco, and
- formal indication for CABG, according to established guideline.
Exclusion Criteria:
- Patients older than 70 years of age, with chronic renal failure, or with unstable angina in the 48 h prior to CABG, moderate or severe valve disease, complex cardiac arrhythmias, stroke, and/or inability to exercise the lower limbs.
Contacts and Locations| Contact: Gaspar R Chiappa, Dr | +555191177267 | gaspar.chiappa@gmail.com |
| Contact: Paulo J Vieira, MSc | +555133596332 | pjvieira28@yahoo.com.br |
| Brazil | |
| Hospital de Clinicas de Porto Alegre | Not yet recruiting |
| Porto Alegre, Rio Grande do Sul, Brazil, 90035-007 | |
| Contact: Gaspar R Chiappa, Dr +555191177267 gaspar.chiappa@gmail.com | |
| Contact: Paulo J Vieira, MSc +555133596332 pjvieira28@yahoo.com.br | |
| Sub-Investigator: Paulo J Vieira, MSc, PT | |
| Principal Investigator: | Gaspar R Chiappa, Dr, ScD | Federal University of Rio Grande do Sul |
More Information
No publications provided
| Responsible Party: | GASPAR ROGERIO DA SILVA CHIAPPA, Principal Investigator, Dr, Hospital de Clinicas de Porto Alegre |
| ClinicalTrials.gov Identifier: | NCT01777659 History of Changes |
| Other Study ID Numbers: | 12-0317 |
| Study First Received: | January 23, 2013 |
| Last Updated: | January 29, 2013 |
| Health Authority: | Brazil: National Committee of Ethics in Research |
Keywords provided by Hospital de Clinicas de Porto Alegre:
|
exercise neuromodulation blood flow exercise capacity |
Additional relevant MeSH terms:
|
Infarction Myocardial Infarction Ischemia Pathologic Processes Necrosis |
Myocardial Ischemia Heart Diseases Cardiovascular Diseases Vascular Diseases |
ClinicalTrials.gov processed this record on May 16, 2013